article thumbnail

Is long-term beta-blocker therapy needed after a heart attack?

Science Daily - Heart Disease

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason.

article thumbnail

Clinical trial finds cell therapy improves quality of life in advanced heart failure

Medical Xpress - Cardiology

Stem cell-based therapy improved quality of life for patients with advanced heart failure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial.

article thumbnail

Questioning Beta-Blocker Interruption After Heart Attack

CardiacWire

Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect. vs. 2.5%), and stroke (1% vs. 1%).

article thumbnail

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

DAIC

Symptomatic PAOD causes poor physical health, loss of mobility and independence, decreased quality of life, premature functional decline and early mortality.2 2 An estimated 10% of patients with PAOD have its most severe form: chronic limb-threatening ischemia (CLTI).

article thumbnail

Beta Blockers May Not Benefit Many Heart Attack Survivors

DAIC

The findings call into question the routine use of beta blockers for all patients following a heart attack, which have stood as a mainstay of care for decades. Approximately 50% of heart attack survivors do not experience heart failure.

article thumbnail

In Your 40s to 60s And Worried About Heart Disease? Here Is What You Can Do.

Dr. Paddy Barrett

. ‘ Snipers Alley ’, it turns out, is an age between 40-60, where mostly males were having fatal heart attacks. These patients were not overly bothered about having a heart attack at age 80, but usually, one of their friends, aged 52 or so, had just had a heart attack, and they did not want to be next.

article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

While the stenting of coronary lesions continues to show a substantial improvement in quality of life for patients with coronary artery disease, ISR still encompasses 10 percent of percutaneous coronary interventions in the U.S. vs. 3.9%, P=0.001), a 49% risk reduction in heart attack at the target vessel (6.4%

Stents 105